Project Grant HT9425261E175
- Federal Grant Award Summary The University of Utah received a $1.39M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2029. The award funds research addressing exposure-induced lung injury and interventions to prevent early lung cancer progression. This three-year project aligns with the DHA's mission to transform healthcare for service members and the American public through...
- The University of Utah has been awarded a $824,512 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from June 1, 2024 to May 31, 2027, will fund research on "Digital Pathology Predictions of Treatment Response in Hormone-Sensitive Prostate Cancer." This project aims to leverage digital pathology techniques to improve the prediction of treatment outcomes for patients with hormone-sensitive...
- Federal Project Grant Award Summary The University of Michigan's Office of Research and Sponsored Projects received a $559,046 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026 through May 31, 2028. This award supports research investigating biased protein phosphatase 2A heterotrimerization in the development and treatment of uveal melanoma. The research will be conducted at the University of...
- The University of California, San Francisco received a $878,043 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on August 15, 2026, with completion scheduled for August 14, 2030. The award supports biochemical and structural targeting research focused on GAQ-mutant melanoma subtypes, representing a translational research initiative aimed at developing innovative therapeutic approaches for this specific melanoma...
- Federal Project Grant Award Summary Yale University received a $522,736 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The award supports research titled "Harnessing Myeloid Cell Ontogeny to Prevent Melanoma Brain Metastasis," to be conducted at Yale's New Haven, Connecticut campus. This project delivers hypothesis-driven biomedical research and development...
- The University of Utah has been awarded a $1,232,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "TARGETING IRON-SULFUR CLUSTER ASSEMBLY A NOVEL VULNERABILITY IN KIDNEY CANCER," will fund research focused on developing new treatment approaches for kidney cancer. The award period runs from July 1, 2024, through June 30, 2028. This federal grant program supports a range of biomedical...
- Federal Project Grant Award Summary Yale University received a $527,262 project grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2029. The research project, titled "Harnessing Myeloid Cell Ontogeny to Prevent Melanoma Brain Metastasis," will be conducted at Yale's New Haven, Connecticut campus and focuses on hypothesis-driven biomedical research addressing cancer...
- Federal Project Grant Award Summary Yale University received a $1.05M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through June 30, 2029. The research initiative, "Harnessing Myeloid Cell Ontogeny to Prevent Melanoma Brain Metastasis," will be conducted at the university's New Haven, Connecticut campus. This award supports hypothesis-driven biomedical research designed to advance...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of Colorado-Denver a Project Grant totaling $904,982 under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2026 through May 31, 2029. The grant supports research focused on the use of unconventional immune cells to treat rare melanomas and to advance understanding of immunotherapy resistance. This research initiative aligns with the DHA's mission to transform healthcare...
- Federal Grant Award Summary The University of Queensland received a $563,707 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research to develop predictive multiomics profiling methodologies for identifying early-stage melanoma cases at elevated risk of recurrence. This research directly aligns with the DHA's mission to advance biomedical solutions...
The University of Utah's Office of Sponsored Projects received a $559,972 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2028. The award funds research on "Preventing Melanoma Metastatic Spread with Engineered Macrophages," a basic and applied biomedical research initiative designed to develop innovative therapeutic solutions for melanoma metastasis. As a primary focus area within the DHA's congressionally-directed medical research portfolio, this project contributes to the agency's mission of transforming healthcare for military service members and the American public through hypothesis-driven research addressing critical oncology challenges. The research deliverables will include investigation of engineered macrophage-based therapeutic approaches to prevent melanoma metastatic progression, with anticipated outputs encompassing biomarker discovery, therapeutic development, and translational research findings. The University of Utah's established expertise in cancer biology research and clinical services, combined with its demonstrated capacity as a major federal research institution, positions it to execute this two-year investigation at its Salt Lake City campus. Award outcomes are expected to contribute to the broader DHA portfolio of cancer immunotherapy and precision medicine research while advancing potential treatment modalities applicable to both military and civilian patient populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $560.0k | 6/10/26 |